MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Consolidator ... Mass Market Scale-up, Global Reach, Public Capital
Consolidators: BioPharmaceuticals
*Isis Pharmaceuticals (NASDAQ: ISIS)-#3 (Biotech-Patent Board-2007),
Organization & Developments: ISIS Pharmaceuticals
Parents
*Isis Pharmaceuticals (NASDAQ: ISIS)-#3 (Biotech-Patent Board-2007),
Children
*Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development of microRNA
Additional information about Isis is available at www.isispharm.com
As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patent
Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbot
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.
Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and can
Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.
The company has successfully commercialized the world's first antisense drug and has 23 drugs in development (2010).
Jumps
*Key People: ISIS Pharmaceuticals
Finance & Acquisitions: ISIS Pharmaceuticals